Source: Communications Biology, by Sam, Ivan J. H.; Rénia, Laurent; Chan, Louisa L. Y.; Ng, Lisa F. P. (September 28, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- The review proposes adapting 2D, 3D, co-culture, and microfluidic joint-on-chip models to study CHIKV joint pathology.
- Primary human synovial fibroblasts supported CHIKV replication and released signals linked to monocyte recruitment and osteoclast-like cell formation.
- Whether resident synovial macrophages protect joints or serve as CHIKV persistence reservoirs remains unknown.
A review in Communications Biology maps out how arthritis research models, including microfluidic joint-on-chip platforms, could help scientists investigate chikungunya virus (CHIKV) joint inflammation. CHIKV causes a short-lived fever in many people, but joint pain and inflammation can persist for years in a substantial subset of patients. The review argues that human-relevant models of cartilage, synovium, immune cells, and the surrounding tissue matrix could reveal disease processes that blood tests and animal studies cannot fully capture. This matters because the tissue-level causes of persistent CHIKV joint disease remain poorly defined.
Why the Joint Needs Its Own Models
CHIKV is an alphavirus spread by Aedes mosquitoes. The World Health Organization reported 445,271 suspected or confirmed CHIKV cases and 155 deaths across 40 countries between January 1 and September 30, 2025, alongside local transmission in Europe.
A joint is more than a hinge between bones. Articular cartilage provides a smooth, load-absorbing surface, while the synovial membrane and fluid lubricate the joint and help supply nutrients to cartilage, which has no blood vessels. These tissues contain cells that can detect infection and release inflammatory signals, making the joint a biologically active site rather than a passive target.
Existing CHIKV studies have clarified important systemic immune responses, particularly interactions between CD4-positive T cells and macrophages. But those approaches offer only part of the picture. The review highlights the need to study how immune cells communicate with fibroblast-like synoviocytes, cartilage cells, and the extracellular matrix, the molecular scaffold surrounding cells within a joint.
CHIKV Arthritis Is Not Rheumatoid Arthritis
CHIKV-related joint inflammation overlaps with rheumatoid arthritis in some ways. Both conditions can involve activated CD4-positive T cells and elevated inflammatory cytokines, which are signaling proteins that coordinate immune responses. Yet similar immune signatures do not mean the diseases operate through the same mechanism.
Rheumatoid arthritis is an autoimmune disease driven by failed immune tolerance and often involves autoantibodies. CHIKV arthritis begins with viral infection and has no consistent autoantibody component. Its inflammatory profile is associated with antiviral chemokines, including CXCL8, CXCL9, and CXCL10, which help recruit and direct immune cells.
This distinction affects model design. A useful CHIKV joint model needs to support viral infection while also capturing the local inflammatory circuitry that may sustain pain, tissue damage, or both after the acute infection has passed.
What Joint Cells May Be Doing
Human fibroblast-like synoviocytes, cells in the synovial lining that normally help maintain lubrication, can support CHIKV replication in laboratory experiments. Infected cells produced viral titers of 105 to 106 plaque-forming units per milliliter and showed virus-related cell damage within days.
These fibroblasts released signals including RANKL, IL-6, IL-8, and MCP-1. RANKL is a protein that can push precursor cells toward becoming osteoclasts, the cells that break down bone. Rather than directly causing all tissue destruction themselves, infected synovial fibroblasts may help launch an inflammatory chain reaction that recruits monocytes and promotes bone-resorbing osteoclast-like cells.
Evidence also points to a role for macrophages. In mouse studies, removing CD4-positive T cells reduced footpad swelling without changing viral load, suggesting these T cells can drive inflammation separately from antiviral control. Viral antigen has also been found in synovial macrophages from one patient 18 months after an initial clinical visit, while nonhuman primate studies detected CHIKV in joint tissue for up to three months after infection.
Building a Joint-on-Chip for Infection Research
The review considers a spectrum of arthritis models: simple two-dimensional cell cultures, three-dimensional cultures, co-cultures that combine different cell types, and microfluidic joint-on-chip systems. A joint-on-chip is a small engineered device that uses tiny fluid channels to organize living cells and their environment. Like a scale model of a working intersection, it can bring several cell types into controlled contact while researchers track how signals, cells, and viruses move between them.
For CHIKV research, the authors identify several design priorities. Models need to make relevant joint cells susceptible to infection, tune the composition of the extracellular matrix, add immune cells that are otherwise missing, and last long enough to examine persistent inflammatory states. Reproducibility will also be essential if different laboratories are to compare results.
Resident synovial macrophages are a particularly important gap. These self-renewing macrophages form a barrier at the synovial interface, help clear debris, and can resolve inflammation. Whether they act mainly as protective sentinels during CHIKV infection or could serve as sites of viral persistence remains unknown.
Why This Matters
Joint-on-chip and related in vitro models could give CHIKV researchers a more direct way to test tissue-specific questions in human cells, from fibroblast-driven immune recruitment to cartilage dysfunction and bone resorption. They may also help separate the effects of viral replication from the immune response that follows it.
The next step is not simply to make a more complex model. It is to build models that include the right cells, matrix conditions, and timescales to test clear biological questions about how CHIKV inflammation begins, persists, and resolves inside the joint.
Topics: Immunity & inflammation · Infectious diseases
Start here: What is a biochip?